Research Article

Estimation of Anti-HIV Activity of HEPT Analogues Using MLR, ANN, and SVM Techniques

Basheerulla Shaik,1 Tabassum Zafar,2 and Vijay K. Agrawal1

1 Department of Applied Sciences, National Institute of Technical Teachers’ Training & Research, Bhopal, Madhya Pradesh 462002, India
2 CSIR-Advanced Materials and Processes Research Institute (AMPRI), Bhopal, Madhya Pradesh 462064, India

Correspondence should be addressed to Basheerulla Shaik; basheerulla.81@gmail.com

Received 6 September 2013; Accepted 14 November 2013

Academic Editor: Bernard Pirotte

Copyright © 2013 Basheerulla Shaik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The present study deals with the estimation of the anti-HIV activity (log 1/C) of a large set of 107 HEPT analogues using molecular descriptors which are responsible for the anti-HIV activity. The study has been undertaken by three techniques MLR, ANN, and SVM. The MLR model fits the train set with $R^2 = 0.856$ while in ANN and SVM with higher values of $R^2 = 0.850, 0.874$, respectively. SVM model shows improvement to estimate the anti-HIV activity of trained data, while in test set ANN have higher $R^2$ value than those of MLR and SVM techniques. $R^2_m$ = metrics and ridge regression analysis indicated that the proposed four-variable model MATSe, RDF080u, T(O⋯O), and MATS5m as correlating descriptors is the best for estimating the anti-HIV activity (log 1/C) present set of compounds.

1. Introduction

Undoubtedly Human immunodeficiency virus (HIV) infection is considered to be a deadly disease by the international community including the World Health Organization (WHO), UNAIDS. The WHO in its reports has said that AIDS has killed more than 25 million people since 1981 which is most the destructive pandemics in the history.

It is also a well-known fact that a lentivirus (a member of the retrovirus family) causes acquired immunodeficiency syndrome (AIDS) [1, 2], damaging immune system and leading to life-threatening infections. A report published in 2007 reveals that approximately 36 million people suffered due to HIV infection. An estimated 2.1 million people were even killed that year including 330,000 children. Another study also reveals that 2.5 million people developed new infections [3–6]. Unfortunately the number of deaths is still rising due to this deadly disease.

Just to overcome the problem scientists are working day and night and a number of RT inhibitors including various nonnucleoside RT inhibitors (NNRTIs) have been discovered as new anti-HIV agents. They have better blocking potential and have been proved to be effective [7–9]. These compounds 1-[2-Hydroxyethoxy) methyl]-6-(phenylthio)-thymine (HEPT) are known for targeting enzyme allosteric site which are less toxic and found to have more stable than nucleoside RT inhibitors.

Many efforts have been made to model the anti-HIV activity of HEPT derivatives in the past using 2D, 3D, and holographic (HQSAR) methods [10–13]. Quantitative structure activity relationship studies were carried out in order to build models for the estimation of binding affinities ($\Delta G_b$) of HEPT and nevirapine analogues with reverse transcriptase [14]. Similarly, Agrawal et al. [15, 16] have successfully reported use of physicochemical as well as topological indices for modeling anti-HIV activities of HEPT analogues.

In continuation to these studies we now report modeling of anti-HIV activity of 1-[2-Hydroxyethoxy) methyl]-6-(phenylthio)-thymine (HEPT) derivatives (Figure 1) using graph theoretical descriptors in which distances and connectivity have been considered. The general structure of HEPT compounds used in the present study is demonstrated in Figure 1. The structural details are presented in Table 1.
Figure 1: General structure of HEPT compounds used in the present study.

This Table also shows the experimental anti-HIV activity of compounds.

A close look of Figure 1 and the activity data presented in Table 1 indicates that the anti-HIV activity mainly dependent upon the type and number of substituent $R_1$ in the benzene moiety.

2. Materials and Methods

2.1. Experimental Data. The structural details as well as anti-HIV activity (log $1/C$) of 107 HEPT analogues are reported in Table I. The RT inhibition data in terms of log $1/C$ have been taken from the literature [12]. All the chemical structures were drawn with the help ACD labs software which helps in the calculation of topological descriptors. These descriptors were calculated using Dragon software using mol file generated by Chemsketch software.

2.2. Selection Molecular Descriptors and Training/Test Set for External Validation. In the present study for estimating the anti-HIV activity of 107 HEPT analogues we have used a pool of descriptors classified into 20 different groups. The descriptor selection is carried out by stepwise regression analysis (forward selection method using NCSS ver. 8 [17]. These selected descriptors are recorded in Table S1 (see Supplementary Material available online at http://dx.doi.org/10.1155/2013/795621). The data set was divided into training and test sets using random sampling technique in which 80% (84 compounds) of the data is taken as training set and the remaining 20% (23 compounds) as test set for the MLR, ANN, and SVM analyses.

3. Results and Discussion

The data (Table 2) was subjected to regression analysis which subsequently gave a correlation matrix showing intercorrelation among the selected descriptors and also with the anti-HIV (log $1/C$) activity. The same has been presented in Table S2. The variable selection for multiple regression analysis has indicated the possibility of using only ten models for modeling the anti-HIV activity (log $1/C$). These models are reported in Table S3. All these models are generated as a result of successive addition of one to ten descriptors. However, correlation of number of descriptors present in the model with $R^2$ (Figure 2) indicated that at the most we can use only four to five descriptors for obtaining statistically most significant model. The statistically significant models obtained from MLR analysis are reported below.

3.1. MLR Results

3.1.1. One-Variable Model. Successive regression analysis indicated that in one-variable model Moran autocorrelation—lag 5/weighted by atomic Sanderson electronegativities (MATS5e) as correlating descriptor is the best model for modelling the log $1/C$. This model is as follows:

\[
\log \frac{1}{C} = -10.9800 (\pm 0.9083) \text{MATS5e} + 4.6503
\]

\[N = 84, \quad \text{Se} = 0.8423, \quad R^2 = 0.6406,\]

\[F\text{-ratio} = 146.132, \quad Q = 1.9501.\] (1)

Here and hereafter $N$ is number of compounds, Se is standard error, $R^2$ is squared correlation coefficient, $R^2_A$ is adjusted $R^2$, $F$-ratio is Fishers ratio, and $Q$ is Pogliani quality factor [18–20].

The negative coefficient of MATS5e indicates that the decrease in its magnitude will enhance the activity (log $1/C$).

3.1.2. Two-Variable Model. When (RDF080u) the unweighted radial distribution function 8.0 is added to the above model the model shows significant improvement in all the parameters. The $R^2$ value changes from 0.6406 to 0.7402. Similarly improvement in adjusted $R^2$ also shows that the addition of (RDF080u) parameter is justified. The improved model is as follows:

\[
\log \frac{1}{C} = -9.5891 (\pm 0.8161) \text{MATS5e} + 0.0899 (\pm 0.0161) \text{RDF080u} + 3.5920
\]

\[N = 84, \quad \text{Se} = 0.7205, \quad R^2 = 0.7402,\]

\[R^2_A = 0.7337, \quad F\text{-ratio} = 115.364, \quad Q = 1.1940.\] (2)
| Comp. No | R₁  | R₂ | R₃ | X   | Obs. log l/C | Est. log l/C (MLR) | Residual (MLR) |
|----------|-----|----|----|-----|-------------|-------------------|----------------|
| 1        | 2-Me| Me |    | CH₂OCH₂CH₂OH | 4.150       | 4.685             | −0.535         |
| 2        | 2-NO₂| Me |    | CH₂OCH₂CH₂OH | 3.850       | 4.495             | −0.645         |
| 3        | 2-OMe| Me |    | CH₂OCH₂CH₂OH | 4.720       | 4.831             | −0.111         |
| 4        | 3-Me | Me |    | CH₂OCH₂CH₂OH | 5.590       | 5.520             | 0.070          |
| 5        | 3-Et | Me |    | CH₂OCH₂CH₂OH | 5.570       | 5.612             | −0.042         |
| 6        | 3-t-Bu| Me |    | CH₂OCH₂CH₂OH | 4.920       | 4.891             | 0.029          |
| 7        | 3-CF₃| Me |    | CH₂OCH₂CH₂OH | 4.350       | 5.011             | −0.661         |
| 8        | 3-F  | Me |    | CH₂OCH₂CH₂OH | 5.480       | 5.132             | 0.348          |
| 9        | 3-Cl | Me |    | CH₂OCH₂CH₂OH | 4.890       | 5.544             | −0.654         |
| 10       | 3-Br | Me |    | CH₂OCH₂CH₂OH | 5.240       | 4.821             | 0.419          |
| 11       | 3-I  | Me |    | CH₂OCH₂CH₂OH | 5.000       | 5.037             | −0.037         |
| 12       | 3-NO₂| Me |    | CH₂OCH₂CH₂OH | 4.470       | 3.976             | 0.494          |
| 13       | 3-OH | Me |    | CH₂OCH₂CH₂OH | 4.090       | 4.882             | −0.792         |
| 14       | 3-OMe| Me |    | CH₂OCH₂CH₂OH | 4.660       | 4.507             | 0.153          |
| 15       | 3,5-Me₂| Me |    | CH₂OCH₂CH₂OH | 6.590       | 6.792             | −0.202         |
| 16       | 3,5-Cl₂| Me |    | CH₂OCH₂CH₂OH | 5.890       | 5.372             | 0.518          |
| 18       | 3-COOMe| Me |    | CH₂OCH₂CH₂OH | 5.100       | 4.033             | 1.067          |
| 19       | 3-COMe| Me |    | CH₂OCH₂CH₂OH | 5.140       | 4.296             | 0.844          |
| 20       | 3-CN | Me |    | CH₂OCH₂CH₂OH | 5.000       | 4.952             | 0.048          |
| 21 H     | CH₂CH=CH₂ |    |    | CH₂OCH₂CH₂OH | 5.600       | 5.849             | −0.249         |
| 22 H     | Et   |    |    | CH₂OCH₂CH₂OH | 6.960       | 6.793             | 0.167          |
| 24 H     | i-Pr |    |    | CH₂OCH₂CH₂OH | 7.230       | 7.380             | −0.150         |
| 25 H     | 3,5-Me₂| Et |    | CH₂OCH₂CH₂OH | 8.110       | 7.691             | 0.419          |
| 27 H     | 3,5-Cl₂| Et |    | CH₂OCH₂CH₂OH | 7.370       | 6.996             | 0.374          |
| 28 H     | Et   |    |    | CH₂OCH₂CH₂OH | 6.920       | 6.595             | 0.325          |
| 30 H     | i-Pr |    |    | CH₂OCH₂CH₂OH | 7.200       | 7.982             | −0.782         |
| 31 H     | 3,5-Me₂| Et |    | CH₂OCH₂CH₂OH | 7.890       | 7.794             | 0.096          |
| 32 H     | 3,5-Me₂| i-Pr |    | CH₂OCH₂CH₂OH | 8.570       | 8.727             | −0.157         |
| 33 H     | 3,5-Cl₂| Et |    | CH₂OCH₂CH₂OH | 7.850       | 6.822             | 1.028          |
| 35 H     | Me   |    |    | CH₂OCH₂CH₂OH | 5.150       | 5.015             | 0.135          |
| 36 H     | Me   |    |    | CH₂OCH₂CH₂OH | 6.010       | 5.218             | 0.792          |
| 37 H     | I    |    |    | CH₂OCH₂CH₂OH | 5.440       | 5.443             | −0.003         |
| 41 H     | CH=CPh₂|    |    | CH₂OCH₂CH₂OH | 6.070       | 6.118             | −0.048         |
| 42 H     | Me   |    |    | CH₂OCH₂CH₂OMe | 5.060      | 5.329             | −0.269         |
| 44 H     | Me   |    | CH₂OCH₂CH₂OCOPh | 5.120     | 5.058             | 0.062          |
| 45 H     | Me   |    | CH₂OCH₂Me   | 6.480       | 5.020             | 1.460          |
| 46 H     | Me   |    | CH₂OCH₂CH₂Cl | 5.820       | 5.247             | 0.573          |
| 47 H     | Me   |    | CH₂OCH₂CH₂N₁ | 5.240       | 5.397             | −0.157         |
| 48 H     | Me   |    | CH₂OCH₂CH₂F  | 5.960       | 4.919             | 1.041          |
| 49 H     | Me   |    | CH₂OCH₂CH₂Me | 5.480       | 5.522             | −0.042         |
|   |   |   |   |   |  
|---|---|---|---|---|---|
| 50 | H | Me | CH$_2$OCH$_3$Ph | O | 7.060 | 6.175 | 0.885 |
| 52 | H | Et | CH$_2$OCH$_3$Me | S | 7.580 | 7.221 | 0.359 |
| 53 | 3,5-Me$_2$ | Et | CH$_2$OCH$_3$Me | O | 8.240 | 8.030 | 0.210 |
| 54 | 3,5-Me$_2$ | Et | CH$_2$OCH$_3$Me | S | 8.300 | 8.293 | 0.007 |
| 56 | 3,5-Me$_2$ | Et | CH$_2$OCH$_3$Ph | O | 8.550 | 8.856 | −0.306 |
| 59 | H | i-Pr | CH$_2$OCH$_3$Me | O | 7.990 | 7.623 | 0.367 |
| 60 | H | i-Pr | CH$_2$OCH$_3$Me | S | 8.140 | 8.479 | −0.339 |
| 61 | H | i-Pr | CH$_2$OCH$_3$Me | O | 5.680 | 5.341 | 0.339 |
| 62 | H | i-Pr | CH$_2$OCH$_3$Me | S | 5.330 | 5.405 | −0.075 |
| 63 | H | Me | CH$_2$OCH$_3$Me | O | 5.660 | 6.443 | −0.783 |
| 64 | H | Me | CH$_2$OCH$_3$Me | S | 5.920 | 6.171 | −0.251 |
| 67 | 3,5-Cl$_2$ | Et | CH$_2$OCH$_3$Me | S | 7.980 | 6.913 | 0.977 |
| 68 | H | Et | CH$_2$O-i-Pr | S | 6.660 | 6.841 | −0.181 |
| 69 | H | Et | CH$_2$O-c-Hex | S | 5.790 | 6.395 | −0.605 |
| 70 | H | Et | CH$_2$OCH$_3$-c-Hex | S | 6.450 | 7.042 | −0.592 |
| 71 | H | Et | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | S | 7.110 | 7.152 | −0.042 |
| 72 | H | Et | CH$_2$OCH$_3$C$_6$H$_4$(4-Cl) | S | 7.920 | 7.718 | −0.210 |
| 73 | H | Et | CH$_2$OCH$_3$C$_6$H$_4$(4-Br) | S | 5.700 | 6.522 | 0.518 |
| 74 | H | Et | CH$_2$O-i-Pr | S | 6.470 | 6.478 | −0.008 |
| 75 | H | Et | CH$_2$O-c-Hex | S | 5.400 | 6.208 | −0.808 |
| 76 | H | Et | CH$_2$OCH$_3$-c-Hex | S | 6.350 | 7.016 | −0.666 |
| 77 | H | Et | CH$_2$OCH$_3$C$_6$H$_4$(4-Br) | S | 7.020 | 6.354 | 0.666 |
| 78 | H | c-Pr | CH$_2$OCH$_3$Me | S | 7.020 | 7.115 | −0.095 |
| 80 | H | c-Pr | CH$_2$OCH$_3$Me | O | 7.000 | 6.865 | 0.135 |
| 81 | H | c-Pr | CH$_2$OCH$_3$Me | S | 3.600 | 4.192 | −0.592 |
| 82 | H | c-Pr | CH$_2$OCH$_3$Me | O | 3.600 | 4.002 | −0.402 |
| 83 | H | c-Pr | CH$_2$OCH$_3$Me | S | 3.560 | 3.526 | 0.034 |
| 89 | 3-CONH$_2$ | Me | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 5.180 | 4.652 | 0.528 |
| 90 | H | COOMe | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 4.740 | 5.393 | −0.653 |
| 91 | H | CONPh | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 4.680 | 5.176 | −0.496 |
| 92 | H | CPh | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 4.740 | 5.048 | −0.668 |
| 93 | H | COCHMe$_2$ | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 4.920 | 5.579 | −0.659 |
| 94 | H | COPh | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 4.890 | 5.085 | −0.195 |
| 95 | H | CCMe | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 4.720 | 5.130 | −0.410 |
| 96 | H | F | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 4.000 | 3.886 | 0.114 |
| 97 | H | Cl | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 4.520 | 4.214 | 0.306 |
| 98 | H | Br | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 4.700 | 4.460 | 0.240 |
| 99 | H | Me | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 4.700 | 5.157 | −0.457 |
| 100 | H | Me | H | O | 3.600 | 4.575 | −0.975 |
| 101 | H | Me | Me | O | 3.820 | 4.535 | −0.715 |

**Table 1:** Continued.

|   |   |   |   |   |  
|---|---|---|---|---|
| 17 | 3,5-Me$_2$ | Me | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | S | 6.660 | 7.005 | −0.345 |
| 23 | H | Pr | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | S | 5.000 | 6.644 | −1.644 |
| 26 | 3,5-Me$_2$ | i-Pr | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | S | 8.300 | 8.499 | −0.199 |
| 29 | H | Pr | CH$_2$OCH$_3$C$_6$H$_4$(4-Me) | O | 5.470 | 6.532 | −1.062 |
Table 1: Continued.

| S. no | Symbol | Descriptors | Meaning |
|-------|--------|-------------|---------|
| 34    | 4-Me   | Me CH₂OCH₂CH₂OH O | 3.660 4.382 −0.722 |
| 38    | H      | CH=CH₂ CH₂OCH₂CH₂OH O | 5.690 6.366 −0.676 |
| 39    | H      | CH=CHPh CH₂OCH₂CH₂OH O | 5.220 5.726 −0.506 |
| 40    | H      | CH₂Ph CH₂OCH₂CH₂OH O | 4.370 5.183 −0.813 |
| 43    | H      | Me CH₂OCH₂OAc O | 5.170 4.385 0.785 |
| 51    | H      | Et CH₂OCH₂Me O | 7.720 7.080 0.640 |
| 55    | H      | Et CH₂OCH₂Ph O | 8.230 7.271 0.959 |
| 57    | H      | Et CH₂OCH₂Ph S | 8.090 7.184 0.906 |
| 58    | 3,5-Me₂ | Et CH₂OCH₂Ph S | 8.140 8.940 0.800 |
| 74    | H      | Me CH₂OCH₂Me O | 3.530 4.726 −1.196 |
| 81    | H      | Me CH₂OCH₂C₅H₁₁ O | 4.460 4.538 −0.078 |
| 82    | 2-Cl   | Me CH₂OCH₂OH O | 3.890 4.738 −0.848 |
| 83    | 3-CH₂OH | Me CH₂OCH₂OH O | 3.720 3.835 −0.115 |
| 86    | 4-NO₂  | Me CH₂OCH₂CH₂O | 3.600 4.794 −1.194 |
| 87    | 4-CN   | Me CH₂OCH₂CH₂O | 3.600 3.588 0.012 |
| 89    | 4-OMe  | Me CH₂OCH₂CH₂O | 3.600 3.569 0.012 |
| 90    | 4-COMe | Me CH₂OCH₂CH₂O | 3.960 4.208 −0.248 |
| 91    | 4-COOH | Me CH₂OCH₂CH₂O | 3.450 3.765 −0.315 |
| 98    | 3-NH₂  | Me CH₂OCH₂CH₂O | 3.600 5.115 −1.515 |

Table 2: Brief description of the descriptors used in the present study.

| S. number | Symbol | Descriptor type | Meaning |
|-----------|--------|----------------|---------|
| 1         | MATS5e | 2D autocorrelation | Moran autocorrelation—lag 5/weighted by atomic Sanderson's electronegativities |
| 2         | RDF080u | RDF descriptors | Radial distribution function 8.0/unweighted |
| 3         | T(O⋯O) | Topological descriptors | The sum of topological distance between (O⋯O) |
| 4         | MATS5m | 2D autocorrelation | Moran autocorrelation—lag 5/weighted by atomic masses |

The above model indicates that decrease in MATS5e and increase in RDF080u will improve the log 1/C values.

3.1.3. Three-Variable Model. When T(O⋯O), which is a parameter which takes care of distance between O atom, is added to the previously stated two-parametric model a three-parametric model is yielded as below. Here the change in $R^2$ and also Q value suggests that the model is better than the earlier one:

$$\log \frac{1}{C} = -7.9071 \pm 0.7818 \text{ MATS5e}$$

$$+ 0.0979 \pm 0.0141 \text{ RDF080u}$$

$$- 0.0162 \pm 0.0031 \text{ T(O⋯O)} + 4.1554,$$  \hspace{1cm} (3)

Here the negative coefficient of T(O⋯O) indicates that the decrease in topological distance between (O⋯O) will favour the exhibition of the anti-HIV activity (log 1/C).

3.1.4. Four-Variable Model. Addition of Moran autocorrelation—lag 5/weighted by atomic masses MATS5m to the above three-parametric model yielded a four-parametric model. A drastic improvement in variance is observed ($R^2$ changes from 0.8053 to 0.8566) The model is given as follows:

$$\log \frac{1}{C} = -5.0974 (\pm 0.8573) \text{ MATS5e}$$

$$+ 0.0862 (\pm 0.0124) \text{ RDF080u}$$

$$- 0.0150 (\pm 0.0027) \text{ T(O⋯O)}$$

$$- 3.2147 (\pm 0.6045) \text{ MATS5m} + 4.2720,$$  \hspace{1cm} (4)

Here the coefficient of MATS5m is negative. This indicates that lower value of MATS5m will favour the log 1/C value for the compounds used in the present study.

A close look at (4) reveals that MATS5e (Moran autocorrelation—lag 5/weighted by atomic Sanderson electronegativities) and MATS5m (Moran autocorrelation—lag 5/weighted by atomic masses) play dominant role in exhibiting the activity. They belong to 2D autocorrelation category. The brief description of the descriptors is given in Table 2.
The predicted log 1/C values of training set compounds using the above four-parametric model are recorded in Table 1 and plotted against their experimental values. Such a correlation is demonstrated in Figure S1. The above reported model (4) has further been used to predict the log 1/C values of remaining 23 compounds which are in test set. Such predicted values are also recorded in Table 1. The predicted $R^2$ value for the model has been obtained by plotting a graph between observed and estimated log 1/C values for the compounds and is demonstrated in Figure S1. The $R^2_{\text{pred}}$ comes out to be 0.814 confirming that the proposed model is meaningful.

The above findings confirm that for the estimation of anti-HIV activity (log 1/C) of present set of compounds a four-variable model containing MATS5e, RDF080u, T(O···O), and MATS5m as correlating descriptors is the most appropriate model. The Ridge analysis (Table 3) indicates that all the Ridge parameters are well within the allowed values indicating that the proposed model is most suitable and statistically significant. Ridge trace and variance inflation factor for the four variable model were recorded in Figures 3 and 4, respectively.

These four descriptors were further used in artificial neural network (ANN) and support vector machine (SVM) techniques. However the methodology, validation techniques, and model performance evaluation by these two methods is previously discussed by Agrawal et al. [21–23]. The observed and predicted values of log 1/C of the training as well as the test data using the ANN and SVM techniques are reported in Table S4.

### 3.2. ANN and SVM Results

Artificial neural network (ANN) and support vector machine (SVM) analyses were carried out using STATISTICA Data Miner software Ver. 10 [24]. The initial architecture of the ANN selected was four neurons in the input layer and three neurons in the hidden layer and one output neuron selected by automated network search function. The input neurons correspond to four selected descriptors of the best MLR model. The optimization was done with 10-fold cross-validation. When the entire training data is trained in the network it gives $R^2 = 0.850$, RMSE = 2.193, and MAE = 0.24. Using the trained network the test set was used for prediction and gives $R^2 = 0.878$, RMSE = 0.823, and MAE = 0.171. A plot of the observed and predicted values of log 1/C of the training as well as the test data using the ANN model is shown in Figure S2.

The SVM regression type I was selected for training the data to obtain capacity $C$ and Epsilon ($\epsilon$) and gamma ($\gamma$) values. In order to find the optimum values of two parameters ($\gamma$ and $\epsilon$), the tenfold cross-validation based on the training set was performed and values giving the lowest RMSE were selected. Using the selected parameters ($\gamma = 0.14$, $\epsilon = 0.20$, and $C = 110$) final training run was carried out on entire training set resulting in predicted log 1/C values. The statistical parameters of this model come out to be RMSE = 1.87, $R^2 = 0.867$, and MAE = 0.393. A plot of the observed and predicted values of log 1/C of the training as well as the test set using the SVM model is shown in Figure S3.
In our study two different variants of this parameter, demonstrates that the SVM model predicts the binding affinity of the compounds more accurately than ANN and MLR models for the train dataset. While for test set prediction, ANN model was better. The proposed models could identify and provide some important information which is responsible for anti-HIV activity. These models could be used for designing new HEPT derivatives.

### 4. Conclusions

A comparison of results from the model performance demonstrates that the SVM model predicts the binding affinity of the compounds more accurately than ANN and MLR models for the train dataset. While for test set prediction, ANN model was better. The proposed models could identify and provide some important information which is responsible for anti-HIV activity. These models could be used for designing new HEPT derivatives.

### Conflict of Interests

The authors report no conflict of interests.

### Disclosure

The authors are responsible for writing of the paper.

### Acknowledgments

Basheerulla Shaik is thankful to NITTTR, Bhopal, for providing the Research facilities. One of the authors (Tabassum Zafar) is thankful to Department of Science & Technology (DST) for providing the INSPIRE fellowship no. IFI10673.

### References

[1] R. A. Weiss, “How does HIV cause AIDS?” Science, vol. 260, no. 5112, pp. 1273–1279, 1993.

[2] D. C. Douek, M. Roederer, and R. A. Koup, “Emerging concepts in the immunopathogenesis of AIDS,” Annual Review of Medicine, vol. 60, pp. 471–484, 2009.

[3] Joint United Nations Programme on HIV/AIDS. Overview of the global AIDS epidemic (PDF). Report on the global AIDS epidemic, 2006.

[4] UNAIDS, WHO (December 2007). 2007 AIDS epidemic update.

[5] A. Levin, Z. Hayouka, A. Friedler, and A. Loyter, “Specific eradication of HIV-1 from infected cultured cells,” AIDS Research and Therapy, vol. 7, article 31, 2010.

[6] M. J. Heravi and F. Parastar, “Use of Artificial neural networks in a qsar study of anti-hiv activity for a large group of HEPT derivatives,” Journal of Chemical Information and Computer Sciences, vol. 40, no. 1, pp. 147–154, 2000.

[7] E. De Clercq, “HIV-1-specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase,” Medicinal Research Reviews, vol. 13, no. 3, pp. 229–258, 1993.

[8] S. D. Young, “Non-nucleoside inhibitors of HIV-1 reverse transcriptase,” Perspectives in Drug Discovery and Design, vol. 1, no. 1, pp. 181–192, 1993.

[9] T. Miyasaka, H. Tanaka, M. Baba et al., “A novel lead for specific anti-HIV-1 agents: 1-(2-Hydroxyethoxy)methyl-6-(phenylthio)thymine,” Journal of Medicinal Chemistry, vol. 32, no. 12, pp. 2507–2509, 1989.

[10] S. Hannongbua, K. Nivesanond, L. Lawtrakul, P. Pungpo, and P. Wolschann, “3D-quantitative structure-activity relationships of HEPT derivatives as HIV-1 reverse transcriptase inhibitors, based on ab initio calculations,” Journal of Chemical Information and Computer Sciences, vol. 41, no. 3, pp. 848–855, 2001.

[11] J. Polanski, R. Gieleciak, T. Magdziarz, and A. Bak, “GRID formalism for the comparative molecular surface analysis:

### Table 4: Values of the $r_m^2$ metrics judging the quality of the model.

| S. number | Method | Sets     | Average $r_m^2$ | $\Delta r_m^2$ |
|-----------|--------|----------|----------------|----------------|
| 1         | MLR    | Train    | 0.799          | 0.114          |
|           |        | Test     | 0.597          | 0.170          |
|           |        | Overall  | 0.732          | 0.133          |
| 2         | ANN    | Train    | 0.825          | 0.079          |
|           |        | Test     | 0.671          | 0.133          |
|           |        | Overall  | 0.799          | 0.045          |
| 3         | SVM    | Train    | 0.817          | 0.102          |
|           |        | Test     | 0.561          | 0.182          |
|           |        | Overall  | 0.731          | 0.125          |
application to the CoMFA benchmark steroids, azo dyes, and HEPT derivatives,” *Journal of Chemical Information and Computer Sciences*, vol. 44, no. 4, pp. 1423–1435, 2004.

[12] J. M. Luco and F. H. Ferretti, “QSAR based on multiple linear regression and PLS methods for the anti-HIV activity of a large group of HEPT derivatives,” *Journal of Chemical Information and Computer Sciences*, vol. 37, no. 2, pp. 392–401, 1997.

[13] P. Pungpo, S. Hannonbua, and P. Wolschann, “Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors,” *Current Medicinal Chemistry*, vol. 10, no. 17, pp. 1661–1677, 2003.

[14] J. Singh, B. Shaik, K. C. Mishra, V. K. Agrawal, and P. V. Khadikar, “Topological estimation of binding affinities (ΔGb) for hept and nevirapine analogues with HIV-1 reverse transcriptase. A molecular connectivity approach,” *Oxidation Communications*, vol. 32, no. 1, pp. 13–27, 2009.

[15] V. K. Agrawal, J. Singh, K. C. Mishra, and P. V. Khadikar, “QSAR study on cytotoxic activities of a series of HEPT analogues,” *Letters in Drug Design and Discovery*, vol. 3, no. 2, pp. 129–137, 2006.

[16] V. K. Agrawal, J. Singh, S. Karmarkar, and P. V. Khadikar, “Qsar studies on some anti HIV-1 drugs: deoxy analogues of HEPT(1),” *Oxidation Communications*, vol. 29, no. 4, pp. 793–802, 2006.

[17] J. Hintze, NCSS 8, NCSS, LLC, Kaysville, Utah, USA, 2012 http://www.ncss.com/.

[18] L. Pogliani, “Structure property relationships of amino acids and some dipeptides,” *Amino Acids*, vol. 6, no. 2, pp. 141–153, 1994.

[19] L. Pogliani, “Modeling with special descriptors derived from a medium-sized set of connectivity indices,” *Journal of Physical Chemistry*, vol. 100, no. 46, pp. 18065–18077, 1996.

[20] L. Pogliani, “From molecular connectivity indices to semiempirical connectivity terms: recent trends in graph theoretical descriptors,” *Chemical Reviews*, vol. 100, no. 10, pp. 3827–3858, 2000.

[21] B. Louis, J. Singh, B. Shaik, V. K. Agrawal, and P. V. Khadikar, “QSAR and ANN studies on prediction of aqueous solubility of heterogeneous set of organic compounds,” *International Journal of Pure and Applied Chemistry*, vol. 3, no. 4, pp. 259–274, 2008.

[22] B. Louis, V. K. Agrawal, and P. V. Khadikar, “Prediction of intrinsic solubility of generic drugs using MLR, ANN and SVM analyses,” *European Journal of Medicinal Chemistry*, vol. 45, no. 9, pp. 4018–4025, 2010.

[23] B. Louis and V. K. Agrawal, “Quantitative Structure-pharamacokinetic relationship (QSPkR) analysis of the volume of distribution values of anti-infective agents from J group of the ATC classification in humans,” *Acta Pharmaceutica Sinica B*, vol. 62, pp. 305–323, 2012.

[24] StatSoft, Inc. (2011). STATISTICA (data analysis software system), version 10, http://www.statsoft.com/.

[25] K. Roy, P. Chakraborty, I. Mitra, P. K. Ojha, S. Kar, and R. N. Das, “Some case studies onapplication of “r²m” metrics for judging quality of quantitative structure-activity relationship predictions: emphasis on scaling of response data,” *Journal of Chemical Information and Computational Science*, vol. 34, pp. 1071–1082, 2013.

[26] A. Golbraikh and A. Tropsha, “Beware of q²!” *Journal of Molecular Graphics and Modelling*, vol. 20, no. 4, pp. 269–276, 2002.